<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597203</url>
  </required_header>
  <id_info>
    <org_study_id>si 082/2019</org_study_id>
    <nct_id>NCT04597203</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial</brief_title>
  <official_title>Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy and safety of using combination of 755-nm picosecond&#xD;
      alexandrite laser and 2% hydroquinone compared with 2% hydroquinone alone for the treatment&#xD;
      of melasma: A randomized split-face controlled trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified melasma area and severity index score(mMASI) - comparing between Picosecond laser 755 nm with 2%HQ and 2%HQ alone for treatment of melasma of using combination of 755-nm picosecond alexandrite laser and 2% hydroquinone</measure>
    <time_frame>6 months</time_frame>
    <description>score range 0-24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melanin index measured by Mexameter® - comparing between Picosecond laser 755 nm with 2%HQ and 2%HQ alone for treatment of melasma</measure>
    <time_frame>6 months</time_frame>
    <description>measuring in au</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average melanin measured by Antera3D® - comparing between Picosecond laser 755 nm with 2%HQ and 2%HQ alone for treatment of melasma</measure>
    <time_frame>6 months</time_frame>
    <description>measuring in au</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction quartile score - comparing between Picosecond laser 755 nm with 2%HQ and 2%HQ alone for treatment of melasma</measure>
    <time_frame>6 months</time_frame>
    <description>score 0 -100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician evaluation quartile score - comparing between Picosecond laser 755 nm with 2%HQ and 2%HQ alone for treatment of melasma</measure>
    <time_frame>6 months</time_frame>
    <description>score 0 -100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of using combination of 755-nm picosecond alexandrite laser</measure>
    <time_frame>6 months</time_frame>
    <description>Monitor side effect from picesecond alexandrite laser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of using 2% hydroquinone</measure>
    <time_frame>6 months</time_frame>
    <description>side effect of topical 2%Hydroquinone use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>split face - left side</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>split face - right side</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755-nm picosecond alexandrite laser with topical 2% hydroquinone</intervention_name>
    <description>treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone</description>
    <arm_group_label>split face - left side</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical 2% hydroquinone</intervention_name>
    <description>treatment one side of the face with topical 2% hydroquinone</description>
    <arm_group_label>split face - right side</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both male and female age 18-60 years&#xD;
&#xD;
          -  Melasma on both cheeks - epidermal or mixed type&#xD;
&#xD;
          -  Fitzpatrick Skin type III-V&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of retinoid or other keratolytic drugs used within 6 months before enrolled&#xD;
&#xD;
          -  History of keloid&#xD;
&#xD;
          -  photosensitivity&#xD;
&#xD;
          -  Immunocompromised host&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>woraphong Manuskiatti, M.D.</last_name>
    <phone>02-419-1000</phone>
    <email>doctorlaser@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chadakan Yan, M.D.</last_name>
    <phone>66882334090</phone>
    <email>chadakanyan4090@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woraphong Manuskiatti, M.D.</last_name>
      <phone>02-419-1000</phone>
      <email>doctolaser@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Woraphong Manuskiatti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rungsima Wanitphakdeedacha, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chadakan Yan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Woraphong Manuskiatti, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

